Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
暂无分享,去创建一个
S. Nomura | A. Sato | T. Kuwata | K. Shitara | A. Kawazoe | Yoshiaki Nakamura | Y. Kuboki | M. Wakabayashi | S. Fukuoka | N. Fujishiro | Y. Mikamoto | H. Shima | Tsukiko Higuchi | Y. Nakamura